Table 2.
Comparison of baseline clinical characteristics of the test cohort based on Brugada syndrome diagnosis after Sodium Channel Blocker Provocation Test.
| Overall (n = 198) |
Negative SCBPT (n = 150) |
Positive SCBPT (n = 48) |
p Value | |
|---|---|---|---|---|
| Age, years | 44.5 ± 13.3 | 44.1 ± 13.6 | 45.8 ± 12.2 | 0.455 |
| Sex Male, % (n) | 70.2 (139) | 73.3 (110) | 60.4 (29) | 0.089 |
| LVEF, % | 58.9 ± 4.3 | 58.2 ± 5.2 | 59.6 ± 4.1 | 0.463 |
| Flecainide administered, mg | 123 ± 12 | 129 ± 14 | 101 ± 11 | <0.0001 |
| Indication for test | ||||
| Suspicious ECG, % (n) | 24.2 (48) | 23.3 (35) | 27.1 (13) | 0.598 |
| Symptoms, % (n) | 6.1 (12) | 6.7 (10) | 4.2 (2) | 0.528 |
| Family history of BrS, % (n) | 59.1 (117) | 60 (90) | 56.3 (27) | 0.646 |
| Family history of sudden cardiac death, % (n) | 10.6 (21) | 10 (15) | 12.5 (6) | 0.624 |